Recently, we demonstrated that prolonged-release pirfenidone (PR-PFD) is an agonist for PPARα [74], and PR-PFD reduces cardiac fibrosis in a mouse NASH model [59]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.